Journal: Clinical Proteomics

Article Title: Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment

doi: 10.1186/s12014-025-09544-6

Figure Lengend Snippet: The figure contains the results of MR and Phe-MR analysis. The significance of causal association between 6 candidates of drug target and AA is evaluated by MR analysis on three independent cohorts ( A ). The results of the meta-analysis based on the statistics from MR are also shown in this forest plot ( A ). The dot plots illustrate the causal effects of identified drug targets, including DEFB1 ( B ), CYD5B2 ( C ), and HGFAC ( D ), on both dichotomous and quantitative phenotypes in the AstraZeneca database. The red dotted line represents the threshold for Bonferroni-corrected p-values

Article Snippet: The primary antibodies used were anti-β-actin (1:10000, Proteintech, 20536-1-AP), anti-GAPDH(1:10000, Proteintech, 60004-1-Ig), anti-DEFB1(1:1000, Proteintech, 14738-1-AP), anti-TGFβ1(1:5000, Proteintech, 81746-2-RR), anti-SMAD2 (1:2000, Proteintech, 12570-1-AP), anti-p-SMAD2(1:1000, Proteintech, 80427-2-RR), and anti-MICA (1:1000, Proteintech, 66384-1-Ig).

Techniques:

Journal: Clinical Proteomics

Article Title: Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment

doi: 10.1186/s12014-025-09544-6

Figure Lengend Snippet: The figure shows the DEFB1 transfection efficiency in HaCaT cells at different timepoints after the transfection. The RNA ( A ) and protein ( B ) expression of DEFB1 both evaluated significantly after 48 h transfection with plasmid

Article Snippet: The primary antibodies used were anti-β-actin (1:10000, Proteintech, 20536-1-AP), anti-GAPDH(1:10000, Proteintech, 60004-1-Ig), anti-DEFB1(1:1000, Proteintech, 14738-1-AP), anti-TGFβ1(1:5000, Proteintech, 81746-2-RR), anti-SMAD2 (1:2000, Proteintech, 12570-1-AP), anti-p-SMAD2(1:1000, Proteintech, 80427-2-RR), and anti-MICA (1:1000, Proteintech, 66384-1-Ig).

Techniques: Transfection, Expressing, Plasmid Preparation

Journal: Clinical Proteomics

Article Title: Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment

doi: 10.1186/s12014-025-09544-6

Figure Lengend Snippet: The alteration of MICA expression and TGFβ/SMAD pathway after the DEFB1 overexpression. The RNA ( A ) and protein expression ( B ) of MICA both increased in HaCaT cells after the DEFB1 overexpression. The TGFβ/SMAD pathway was enriched in the AA samples of GSE212447 ( C and D ). The same pathway activation was also detected after the DEFB1 overexpression ( E )

Article Snippet: The primary antibodies used were anti-β-actin (1:10000, Proteintech, 20536-1-AP), anti-GAPDH(1:10000, Proteintech, 60004-1-Ig), anti-DEFB1(1:1000, Proteintech, 14738-1-AP), anti-TGFβ1(1:5000, Proteintech, 81746-2-RR), anti-SMAD2 (1:2000, Proteintech, 12570-1-AP), anti-p-SMAD2(1:1000, Proteintech, 80427-2-RR), and anti-MICA (1:1000, Proteintech, 66384-1-Ig).

Techniques: Expressing, Over Expression, Activation Assay

Journal: Clinical Proteomics

Article Title: Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment

doi: 10.1186/s12014-025-09544-6

Figure Lengend Snippet: The plot depicts the process of virtual selection. The TCM ingredients in TCMSP were filtrated based on their OB, dl, and, BBB. The remained TCM ingredients with MW under 500 were prioritized according their affinity with DEFB1. The visualized 3D graph picture shows the protein (the green structure) wrapping the Cimigenol particle (the yellow structure) ( C ). Residues Gly-30 A bind the Cimigenol through the hydrogen bonds (blue line) while the Lys-31B binds the Cimigenol through both hydrogen bonds and hydrophobic interactions (grey dotted line). The table contained detailed information of the interacting bonds between Cimigenol and DEFB1( D )

Article Snippet: The primary antibodies used were anti-β-actin (1:10000, Proteintech, 20536-1-AP), anti-GAPDH(1:10000, Proteintech, 60004-1-Ig), anti-DEFB1(1:1000, Proteintech, 14738-1-AP), anti-TGFβ1(1:5000, Proteintech, 81746-2-RR), anti-SMAD2 (1:2000, Proteintech, 12570-1-AP), anti-p-SMAD2(1:1000, Proteintech, 80427-2-RR), and anti-MICA (1:1000, Proteintech, 66384-1-Ig).

Techniques: Selection

Journal: Clinical Proteomics

Article Title: Multi-omics analyses, cell experiments, and network pharmacology tools identified key proteins and candidate drugs for alopecia areata treatment

doi: 10.1186/s12014-025-09544-6

Figure Lengend Snippet: The Cimigenol treatment inhibited the TGFβ/SMAD2 pathway activation and increased level of MICA induced by DEFB1 in vitro. ( A ) Cell viability of HaCaT cells in different concentrations of Cimigenol. ( B ) The Cimigenol treatment reversed the increase in the protein level of DEFB1, TGFβ1, p-SMAD2, and MICA after the transfection

Article Snippet: The primary antibodies used were anti-β-actin (1:10000, Proteintech, 20536-1-AP), anti-GAPDH(1:10000, Proteintech, 60004-1-Ig), anti-DEFB1(1:1000, Proteintech, 14738-1-AP), anti-TGFβ1(1:5000, Proteintech, 81746-2-RR), anti-SMAD2 (1:2000, Proteintech, 12570-1-AP), anti-p-SMAD2(1:1000, Proteintech, 80427-2-RR), and anti-MICA (1:1000, Proteintech, 66384-1-Ig).

Techniques: Activation Assay, In Vitro, Transfection